NeokenBio Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Employees
  • 16

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $7.51M

  • Investors
  • 11

NeokenBio General Information

Description

Developer of drugs intended to treat intractable diseases with efficacy from Hemp. The company develops drugs using NOID and localizes epilepsy drugs that help in the treatment of brain diseases, enabling healthcare companies to provide patients with effective drugs to cure diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 506 Global Center
  • 117-3, Hoegi-ro
  • Seoul, Dongdaemun-gu 02455
  • South Korea
+82
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
Biotechnology
Corporate Office
  • 506 Global Center
  • 117-3, Hoegi-ro
  • Seoul, Dongdaemun-gu 02455
  • South Korea
+82

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

NeokenBio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC (Series B) 25-Sep-2023 $7.51M Completed Generating Revenue
3. Early Stage VC (Series A) 26-Jul-2022 Completed Generating Revenue
2. Accelerator/Incubator 31-Oct-2021 Completed Generating Revenue
1. Seed Round 30-Sep-2021 Completed Generating Revenue
To view NeokenBio’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

NeokenBio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

NeokenBio Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
Blianx Investment Venture Capital Minority
Medytox Solutions Corporation Minority
Prologue Ventures Corporate Venture Capital Minority
QUAD Investment Management Hedge Fund Minority
BM Ventures Venture Capital Minority
You’re viewing 5 of 11 investors. Get the full list »

NeokenBio Investments (1)

NeokenBio’s most recent deal was a Joint Venture with Drug Discovery (Kiss of Beauty / NeokenBio). The deal was made on 03-Jun-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Drug Discovery (Kiss of Beauty / NeokenBio) 03-Jun-2024 Joint Venture Drug Discovery
To view NeokenBio’s complete investments history, request access »

NeokenBio FAQs

  • When was NeokenBio founded?

    NeokenBio was founded in 2021.

  • Where is NeokenBio headquartered?

    NeokenBio is headquartered in Seoul, South Korea.

  • What is the size of NeokenBio?

    NeokenBio has 16 total employees.

  • What industry is NeokenBio in?

    NeokenBio’s primary industry is Drug Discovery.

  • Is NeokenBio a private or public company?

    NeokenBio is a Private company.

  • What is NeokenBio’s current revenue?

    The current revenue for NeokenBio is .

  • How much funding has NeokenBio raised over time?

    NeokenBio has raised $11M.

  • Who are NeokenBio’s investors?

    Blianx Investment, Medytox Solutions, Prologue Ventures, QUAD Investment Management, and BM Ventures are 5 of 11 investors who have invested in NeokenBio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process